See newly added Content Pack – Mitochondrial Dysfunction & Neurodegenerative Diseases below!
What’s the one breakthrough you want to see in the neurodegenerative field over the next 5 years?
Matthew E. Kennedy PhD Director, Neuroscience
Merck Research Laboratories, Boston, MA
On behalf of the BACE inhibitor discovery and development program
Director Research Programs
Micheal J. Fox Foundation
Michael Irizarry M.D., VP Early Clinical Development, Neurosciences,
Eli Lilly and Company
With the shear amount of clinical failures and loss of money spent on Alzheimer’s and other neurodegenerative diseases, many have argued that the issue lies somewhere else entirely.
Mitochondria have emerged as a pivotal convergence point for neurodegeneration – a potential red herring for disease pathogenesis.
Enjoy this content pack of specially selected papers by the World CNS Speaker Faculty.
This content pack contains the following articles:
3) A de novo compound targeting a-synuclein improves deficits in models of Parkinson’s Disease (Wrasidlo et al 2016)
This presentation pack includes 3 presentations on the following topics:
Applying our Knowledge of Genetic Factors in Parkinson’s Disease: Linking Pathophysiological Mechanisms to Sporadic Cases & Driving the Discovery of Novel Therapeutics
Warren Hirst, now Director Neurology Research, Biogen
[18F]MK-6240, A Novel Tau PET tracer: From Discovery to Clinical Evaluation
Cyrille Sur, Executive Director & Neuroscience Imaging Lead, Merck & Co.
Mobile Health: Utility in Neuroscience Early Development
Gabriel Vargas, Executive Medical Director Neuroscience Therapeutic Area, Amgen